Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II perioperative adebrelimab + carboplatin + nab-paclitaxel + recaticimab in resectable NSCLC
ChiCTR2400086014Phase 2Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Jun 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, carboplatin, paclitaxel and recaticimab in non-small cell lung cancer (NSCLC), sponsored by Beijing Chest Hospital. Primary endpoint: pathological complete response. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
adebrelimabcarboplatinpaclitaxelrecaticimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400086014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086014.